FEATURED SEARCH: HCC
Abstracts just in from the 2010 American Society for Clinical Oncology meeting on gastrointestinal cancers include several new reports about hepatocellular carcinoma (HCC). Among them, oncological surgeons from Japan discuss their experience using a hybrid ablation strategy for patients with multiple HCC, including a mix of percutaneous and endoscopic approaches to minimize the risk of dissemination and puncture. Scroll down to find many other interesting studies on the topic. (You can target abstracts from ASCO meetings by using the Meeting Abstracts articles category.)
RESULT: Hybrid ablation therapy for multiple hepatocellular carcinomas
ASCO 2010 Gastrointestinal Cancers Symposium | Jan 19, 2010
In another report, a multicenter team from Europe compared modified WHO and modified RECIST guidelines for assessment of HCC responses to therapy, using data on patients from a clinical trial. They found that the RECIST guidelines may be preferable, and may explain a disconnect between time to progression and overall survival that arises when using the WHO criteria.
RESULT: Comparison of tumor responses by modified WHO and new RECIST criteria from a phase II study of first-line brivanib in hepatocellular carcinoma (HCC)
ASCO 2010 Gastrointestinal Cancers Symposium | Jan 19, 2010
Also in this search is a recent review about assessing and addressing the risk of recurrence among HCC patients given liver transplantation. (The article below is an editorial about the review; the link to the review itself is at the bottom of the screen, beneath the comments box.)
RESULT: Getting a Handle on Post-transplant Recurrence of HCC
Cancer Network | Dec 17, 2009
___________________________________________________________
OTHER RECENT SEARCHES ON SEARCHMEDICA
Search: lymphangitis
After observing 116 patients for a year after breast cancer surgery involving axillary node dissection, researchers from Spain found that physiotherapy including manual lymph drainage, massage, and shoulder exercises can significantly reduce the risk of postoperative lymphedema when begun shortly after surgery. (The British Medical Journal offers full text of this article for free.)
RESULT: Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial
British Medical Journal | Jan 10, 2010
Search: CINV
By adding the 5HT3-receptor antagonist palonosetron to dexamethasone on day one of treatment, researchers found that on the following two days placebo was as good as dexamethasone in preventing chemotherapy-induced adverse effects. This obviously offers a way to reduce the risk of corticosteroid-induced adverse effects of the drug given to ease the chemotherapy-induced nausea and vomiting (CINV).
RESULT: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy
Annals of Oncology | Jan 15, 2010
Posted by smnewsletters 
